LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

uniQure NV

Gesloten

17.44 0.29

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17

Max

17.7

Belangrijke statistieken

By Trading Economics

Inkomsten

5.9M

-38M

Verkoop

3.7M

5.3M

Winstmarge

-716.819

Werknemers

209

EBITDA

-4.5M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+132.76% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

76M

896M

Vorige openingsprijs

17.15

Vorige sluitingsprijs

17.44

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

uniQure NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2024, 15:18 UTC

Belangrijke Marktbewegers

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Peer Vergelijking

Prijswijziging

uniQure NV Prognose

Koersdoel

By TipRanks

132.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.57 USD  132.76%

Hoogste 70 USD

Laagste 24 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor uniQure NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technische score

By Trading Central

10.05 / 14.75Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
help-icon Live chat